A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Required: EGFR wild-type

documentation of absence of tumor-activating EGFR mutations [eg, DEL19 or L858R]

Excluded: ALK rearrangement

presence of anaplastic lymphoma kinase (ALK) gene rearrangements

Cannot have received: neoadjuvant therapy

Exception: except as specified in protocol (neoadjuvant chemotherapy and pembrolizumab followed by surgery allowed if no pCR)

Received prior neoadjuvant therapy for their current NSCLC diagnosis

Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy

Received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein [CTLA-4], OX-40, CD137)

Cannot have received: systemic anticancer therapy

Exception: other than what is specified in this protocol

Received prior systemic anticancer therapy including investigational agents other than what is specified in this protocol

Cannot have received: cancer vaccine

Received prior treatment with a cancer vaccine

Cannot have received: radiation therapy

Exception: within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids

Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids